‘Very Impressive’ Survival With Combo in First-Line Prostate Cancer Study

By News Health
53 minutes Ago

(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…

Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120096

Author :

Publish date : 2026-02-27 22:43:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

I take 120 tablets a week after mesh operation

More Parents Say 'No' to Vitamin K Shots for Newborns

GOP Physician Lawmaker Puts Insurers on Notice

Single-Tablet Combo Matched Complex Regimens in Older HIV Patients

Early Bleeding Alone Not Tied to Pregnancy Loss Risk

Bariatric Surgery Beats GLP-1s for Heart Protection in T2D